Tirzepatide 10mg 99% pure — GLP-1/GIP dual agonist entry format

Zoom

10mg44,00 €20mg83,00 €

44,00 €

Tax included • Free delivery from 99€

+2,20 € in loyalty cashback, with an account. Create my account

Only 4 left, flying off the shelf!

Next dispatch: Tuesday, September 8

Subscription

39,60 €-10 %instead of 44,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

What the parcel contains

One sealed vial of Tirzepatide 10mg, lyophilised, without individual labelling.

What you also need

Bacteriostatic water for reconstitution and 1 ml precision syringes graduated in 100 units, sold separately. The vial alone cannot be used as is.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Cartouches 3 mlx59,90 €

Aiguilles Stylo Injecteurx1010,90 €

Tirzepatide 10mg is the entry format giving access to the GLP-1/GIP dual agonism documented by SURPASS and SURMOUNT without heavy volumetric commitment. This vial is sized for titration phases and short exploratory research cycles, typically 4-8 weeks after reconstitution. For researchers discovering the molecule or calibrating a first protocol, the 10mg format validates individual tolerance, adjusts titration to subject physiology, and measures early metabolic markers (fasting glucose, HbA1c, body mass, waist circumference, lipids) before committing to a long cycle. Its compact format also minimizes financial risk if discontinuation is decided early in the cycle.

Range positioning: 10mg is the rational entry point vs 15mg (standard SURMOUNT-1 target dose), 30mg (3-month long-cycle), or 60mg (6-month mega-cycle). Reconstituted at 2 mL bacteriostatic water, it delivers 5 mg/mL; at 1 mL it delivers 10 mg/mL for researchers wishing to minimize injected volume. At target dose 10mg/week (SURMOUNT-1 plateau week 13-16), one vial covers exactly 1 full week; at 5mg/week (plateau week 5-8) it covers 2 weeks; at 2.5mg initial dose, 4 weeks. The format thus suits both calibration and short-segment validation equally.

Science

01
Mechanism of action

Tirzepatide is the first marketed dual incretin-mimetic agonist. Its 39-residue sequence derives from native human GIP (Glucose-dependent Insulinotropic Polypeptide), with engineered modifications that confer simultaneous high affinity at two G-protein-coupled receptors: GLP-1R and GIPR. Coskun and colleagues (Mol Metab 2018) described the rational design: Aib substitutions at positions 2 and 20 blocking DPP-4 cleavage, and a C20 diacid fatty-acyl chain attached to Lys20 via a gamma-glutamate linker that anchors the molecule to serum albumin and extends the half-life to roughly 117 hours in humans.

Tirzepatide biology is not simply the sum of GLP-1 plus GIP activity. The GIPR-biased sequence (picomolar-range EC50 at GIPR, sub-nanomolar at GLP-1R) creates a qualitatively distinct signaling signature. Willard et al. (JCI Insight 2020) demonstrated that tirzepatide recruits beta-arrestin less strongly at GLP-1R than native GLP-1, producing a bias toward Galpha-s / cAMP signaling that may limit receptor desensitization. At GIPR, conversely, tirzepatide behaves as a full agonist. This signaling architecture partly explains the clinical metabolic superiority observed over single GLP-1 agonists.

The GIP arm adds mechanisms absent from single agonists. In adipose tissue, GIPR activation stimulates postprandial lipogenesis and triglyceride clearance while improving insulin sensitivity in subcutaneous adipocytes. In the central nervous system, GIPR neurons in the arcuate and paraventricular nuclei modulate appetite additively with GLP-1R neurons. Preclinical models (GIPR-KO mice, obese rats) suggest that GIP/GLP-1 co-activation increases thermogenic energy expenditure through brown adipose tissue, contributing to weight loss beyond caloric restriction.

At the pancreatic level, the incretin effect is potentiated synergistically: tirzepatide administration in type 2 diabetic subjects triggers glucose-dependent insulin secretion exceeding a reference GLP-1 mono-agonist, without clinical hypoglycemia (Heise 2022 Diabetes Care). GLP-1 glucagonostatic action stabilizes fasting glycemia. Gastric emptying is also slowed, contributing to satiety but demanding attention to drug interactions and gastrointestinal discomfort during rapid titrations.

Pharmacokinetics justify the weekly regimen. Cmax is reached 24-72 hours post-injection depending on dose, terminal half-life 117 hours, steady-state achieved within 4 weeks on a fixed weekly dose. Clearance is essentially proteolytic (no significant CYP450 biotransformation), limiting pharmacokinetic interactions. In research contexts this pharmacokinetic window is precious: weekly administration produces near-stationary plasma concentrations, facilitating protocol standardization and reproducibility of cohort measurements.

Clinical data

02Clinical studies

The tirzepatide clinical program spans two arms: type 2 diabetes (SURPASS) and obesity without diabetes (SURMOUNT). Phase III trial density is substantial and positions the molecule as one of the best-documented incretin agents to date.

SURPASS-1 (Rosenstock 2021, Lancet) compared tirzepatide 5/10/15mg weekly to placebo in 478 drug-naive T2D patients over 40 weeks. HbA1c reductions: -1.87% (5mg), -1.89% (10mg), -2.07% (15mg) vs -0.04% placebo. Weight loss: -7.0 to -9.5 kg dose-dependent. SURPASS-2 (Frias 2021, NEJM) was the pivotal head-to-head trial against semaglutide 1mg in 1879 patients over 40 weeks. Tirzepatide 15mg produced HbA1c reduction -2.30% vs -1.86% for semaglutide 1mg, and weight loss -11.2 kg vs -5.7 kg. This trial established the metabolic superiority of the dual agonist over the reference GLP-1 mono-agonist.

SURPASS-3 (Ludvik 2021) added tirzepatide to metformin vs insulin degludec in 1437 patients over 52 weeks: marked superiority in HbA1c reduction and weight loss, with fewer hypoglycemia events. SURPASS-4 (Del Prato 2021, Lancet) extended evaluation to high cardiovascular risk patients over 104 weeks: durable HbA1c and weight reductions, reassuring cardiovascular profile. SURPASS-5 (Dahl 2022, JAMA) tested addition to insulin glargine: HbA1c -2.40% (15mg), weight -10.9 kg, substantial metabolic improvement.

The SURMOUNT program targets obesity without diabetes. SURMOUNT-1 (Jastreboff 2022, NEJM) enrolled 2539 adults BMI >= 30 (or >= 27 with comorbidities) over 72 weeks. Mean weight loss: -15.0% (5mg), -19.5% (10mg), -20.9% (15mg) vs -3.1% placebo. 50.1% of 15mg patients reached >= 20% weight loss, 36.2% reached >= 25%. These figures position tirzepatide at an unprecedented level for pharmacological obesity treatment, approaching reductions observed in sleeve gastrectomy bariatric surgery.

SURMOUNT-2 (Garvey 2023, Lancet) validated the effect in diabetic obese patients (-13.4% @15mg over 72 weeks). SURMOUNT-3 (Wadden 2023, Nat Med) showed that after a 12-week intensive diet lead-in, adding tirzepatide 10/15mg generated -18.4% additional loss over 72 weeks vs +2.5% placebo. SURMOUNT-4 (Aronne 2024, JAMA) tested withdrawal: after 36 weeks of maximal tirzepatide followed by 52 weeks of maintenance or discontinuation, the discontinuation group regained 14.0% of body weight while the maintenance group lost an additional 5.5%. Practical conclusion: ongoing therapy is required to preserve benefit, consistent with obesity as a chronic disease.

Ancillary data support systemic benefits. SURPASS-CVOT (ongoing cardiovascular trial, results expected 2025-2026) will compare tirzepatide to dulaglutide in 13299 high-CV-risk T2D patients. SYNERGY-NASH (Loomba 2024, NEJM) documented MASH resolution without fibrosis worsening in 51.8% of tirzepatide 10mg patients vs 9.8% placebo. Effects on sleep apnea (SURMOUNT-OSA, Malhotra 2024 NEJM) show a 55% reduction in apnea-hypopnea index at 52 weeks. These data sketch a cross-cutting therapeutic profile few agents share.

In research these references structure protocol design: titration regimens used in trials (2.5mg weeks 1-4 then +2.5mg every 4 weeks to target dose) serve as a methodological framework for exploratory cohorts, and stopping criteria (severe gastrointestinal events, pancreatitis, hypersensitivity reactions) inform exclusion criteria for observational work.

1
ObésitéTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1 Investigators) · New England Journal of Medicine · 2022
2
ComparaisonTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, Davies MJ, Rosenstock J, et al. (SURPASS-2 Investigators) · New England Journal of Medicine · 2021
3
Double agonisteEfficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
Rosenstock J, Wysham C, Frías JP, et al. · The Lancet · 2021

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

The SURMOUNT-1 reference protocol (Jastreboff 2022 NEJM) is the usual matrix. Phase 1 titration (weeks 1-20): 2.5mg weekly W1-4, 5mg W5-8, 7.5mg W9-12, 10mg W13-16, 12.5mg W17-20, 15mg W21+. With a 10mg vial, researchers often begin with the initial phase: 2.5mg/week for 4 weeks (one vial covers the whole period), then transition to 15mg or repeat a 10mg to reach the 5mg plateau.

Option A — initial titration protocol (4 weeks, 2.5mg/week): reconstitute 10mg with 2 mL bacteriostatic water (concentration 5 mg/mL). Draw 0.5 mL (50 units on U100 syringe) delivers 2.5mg. One vial = 4 doses of 2.5mg = 4 weeks of initial titration. Ideal for validating individual tolerance before long commitment.

Option B — 10mg plateau protocol (1 week): reconstitute 10mg with 1 mL (concentration 10 mg/mL). Draw 1 mL (100 units) delivers 10mg in a single injection. One vial = 1 week at target dose 10mg (SURMOUNT-1 W13-16 plateau). Option for researchers in progressive up-titration wishing to validate this specific plateau.

Option C — intermediate 5mg/week protocol (2 weeks): reconstitute 10mg with 2 mL (5 mg/mL). Draw 1 mL (100 units) delivers 5mg. One vial = 2 weeks at SURMOUNT-1 W5-8 plateau.

Injection site: rotate across 4 abdominal subcutaneous zones (right upper, right lower, left upper, left lower quadrants), minimum 2.5 cm from navel. Alternate weekly to prevent lipohypertrophy. Anterolateral thigh and flank are valid alternatives. Bevel up, angle 45-90 degrees depending on skinfold thickness. Aspirate if unsure, inject slowly (5-10 seconds), hold 10 seconds before withdrawal.

Minimum monitoring: weekly weight at fixed time, waist every 15 days, fasting glucose every 4 weeks (or continuous via CGM for advanced protocols), HbA1c at W0, W12, W24. Daily adverse event journal for the first 4 weeks (nausea, satiety, fatigue, bowel movements).

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	10 mg/ml	10 UI = 1 mg
2 ml	5 mg/ml	40 UI = 2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Lyophilized tirzepatide stability is robust as long as the cold chain is maintained. The product stores up to 24 months at 2-8 degC, protected from light in its original packaging. Freezing below -20 degC, though sometimes practiced for extended stockpiles, adds no documented benefit for the intact peptide and introduces freeze-thaw cycle risk if storage is unstable. Transient ambient temperature (24-48h below 25 degC) is tolerable during transport or brief refrigeration failure, but any exposure beyond this threshold must be logged.

After reconstitution with bacteriostatic water, the solution stores for 21 to 28 days at 2-8 degC, still protected from light. The 0.9% benzyl alcohol in bacteriostatic water preserves microbiological sterility but does not halt chemical peptide degradation, which continues slowly even under refrigeration. Dominant degradation pathways for tirzepatide are methionine oxidation (Met27), asparagine deamidation and glutamine deamidation, along with oligomer formation via hydrophobic interactions involving the C20 acyl chain. A 5-10% activity loss after 28 days is expected, usable in research but to be factored into dose-response calculations over extended cycles.

In the laboratory, a few operational rules are essential. (1) Minimize fridge entries/exits: every thermal shock accelerates degradation. Remove the vial just before sampling, return to cold storage within 10 minutes. (2) Never shake vigorously: the C20 chain readily generates oligomers if the solution is subjected to shear (shaker, vortex). Tilt gently or let dissolve spontaneously. (3) Light protection: amber glass vials from original packaging are effective; if transferring to clear tubes, wrap in aluminum. (4) Document the cold chain with a temperature logger on the dedicated peptide fridge, with SMS alert on threshold breach.

In cohort production, a strict dating protocol is required. Label each reconstituted vial with date, time, final concentration, initial lot, and operator initials. Plan samplings to exhaust the vial before day 28 as priority, minimizing reject percentage. For long cycles (> 8 weeks), prefer volumetric formats adapted to cycle duration (30mg or 60mg) rather than chaining 10 or 15mg reconstitutions, which multiply manipulations and contamination risks. The economical format matched to cycle length is the best anti-degradation and anti-waste strategy.

01Why is tirzepatide called a "dual agonist" and what does it change in practice?

Tirzepatide simultaneously activates two incretin receptors: GLP-1R and GIPR. GLP-1 alone (semaglutide, liraglutide) acts mainly on central satiety, insulin secretion, and gastric emptying. Adding the GIP arm activates additional pathways: postprandial adipose lipogenesis, triglyceride clearance, brown adipose tissue thermogenesis, and amplified pancreatic incretin signaling. The SURPASS-2 head-to-head trial (Frias 2021 NEJM) demonstrated superiority of +0.44% HbA1c and +5.5 kg additional weight loss for tirzepatide 15mg vs semaglutide 1mg, concretely translating the dual agonism value.

02What volume of bacteriostatic water should be used to reconstitute a tirzepatide vial?

Volume depends on format and target concentration. For a 10mg vial, 2 mL bacteriostatic water yields 5 mg/mL (covers 2 full cycles of SURPASS-1 mid dose). For 15mg, 2 mL yields 7.5 mg/mL, or 3 mL yields 5 mg/mL. For 30mg long-cycle, 3 mL = 10 mg/mL, 4 mL = 7.5 mg/mL, 6 mL = 5 mg/mL. For 60mg mega-cycle, 6 mL = 10 mg/mL. Practical rule: aim for a concentration that gives 20-50 units on a U100 syringe for the target dose, minimizing measurement error.

03How long can reconstituted tirzepatide be stored, and what signs indicate degradation?

The reconstituted solution stores 21-28 days at 2-8 degC protected from light. The benzyl alcohol in bacteriostatic water preserves microbiological sterility, not chemical integrity. Degradation pathways: Met27 oxidation, asparagine deamidation, oligomerization via the C20 chain. Visual degradation signs: cloudiness, precipitate, crystals, color shift (yellow or amber), flocculation on gentle swirl. A healthy solution remains clear and colorless. If in doubt, discard and reconstitute a new vial. Expected activity loss after 28 days: 5-10%.

04Why must tirzepatide be titrated progressively?

Titration is dictated by gastrointestinal tolerance. At full dose from start, 40-60% of subjects experience severe nausea, vomiting, diarrhea, fatigue; early discontinuation climbs to 15-20%. SURMOUNT-1 protocol requires: 2.5mg weekly for weeks 1-4, then 5mg weeks 5-8, then 7.5mg 9-12, then 10mg 13-16, then 12.5mg 17-20, then 15mg target from week 21. This progression allows gastrointestinal receptors to adapt, reducing adverse event rates to 5-8% on target dose, and preserves adherence. In research, respecting this schedule is indispensable for usable data.

05What are key drug interactions and contraindications for tirzepatide?

Absolute contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome (preclinical signal in rodents on thyroid C-cells, not confirmed in humans but precautionary), acute or chronic pancreatitis. Interactions: slowed gastric emptying alters absorption of narrow-therapeutic-window oral drugs (warfarin, digoxin, immunosuppressants). Combined oral contraceptives see reduced absorption in the 4 weeks following each dose increment; supplementary barrier contraception is recommended. Particular vigilance on sulfonylureas and insulin (potentiated hypoglycemia).

06Can tirzepatide be combined with other research peptides (BPC-157, TB-500, CJC-1295)?

Combination data are limited to exploratory research contexts. Profiles are orthogonal: BPC-157 and TB-500 target tissue repair and healing with no known pharmacodynamic interaction with incretin mimetics. CJC-1295 (GHRH agonist) modifies the GH/IGF-1 axis and could interact with glucose metabolism under tirzepatide, requiring enhanced glycemic monitoring. No direct pharmacokinetic interaction is expected (tirzepatide clears proteolytically, not via CYP450). In research, precisely documenting each combination and observed effects is essential for data value.

07Which format should I choose for a long cohort protocol (16+ weeks)?

For a 16-week or longer cycle at 15mg target dose, prefer the 60mg format: one vial covers 4 full weeks at full dose (4 x 15mg), meaning 3 vials for a 12-week post-titration cycle. This reduces the number of reconstitutions from 12 (if 10mg) to 3 (if 60mg), divides contamination and degradation risk by 4, and lowers per-mg cost. For 8-16 week cycles, 30mg is a good compromise. For short cycles (< 8 weeks) or initial titration phase, 10mg or 15mg suffice. General rule: one format per logical phase (titration / target dose / maintenance).

08Why should tirzepatide never be mixed in the same syringe as insulin or another peptide?

Tirzepatide formulations include a citrate pH buffer and excipients (phenol, methionine antioxidant) optimized for its stability. Mixing with insulin (neutral or acidic pH depending on type) can trigger precipitation, C20 chain oligomerization, and activity loss. Mixing with another peptide (BPC-157, TB-500) may trigger hydrophobic interactions and cross-degradation. In research, administration must always occur as two separate injections (different sites, fresh syringes), spaced at least several minutes apart to isolate kinetics and cleanly document each agent's effects.

Benchmark

Similar peptides

Versus semaglutide (GLP-1 mono-agonist): head-to-head superiority demonstrated in SURPASS-2 (Frias 2021 NEJM). Tirzepatide 15mg beats semaglutide 1mg by +0.44% additional HbA1c and +5.5 kg additional weight loss. The GIP arm contributes measurably to visceral fat and energy expenditure. Limit: slower titration (5 steps to 15mg) and stricter gastrointestinal tolerance in the first weeks.

Versus retatrutide (GLP-1/GIP/GCGR triple agonist): retatrutide adds a glucagon arm that stimulates hepatic thermogenesis and lipolysis. Phase II data (Jastreboff 2023 NEJM) show -24.2% at 12mg/48w vs -20.9% for tirzepatide 15mg/72w, a notable gap. But retatrutide is newer, with fewer long-term data, and the GCGR component demands heightened vigilance on hepatic function. Tirzepatide retains the advantage of clinical maturity (>400 publications) and better-mapped tolerance profile.

Versus liraglutide 3mg (Saxenda): liraglutide is a daily GLP-1 mono-agonist with -8% weight loss over 56 weeks (Pi-Sunyer 2015 NEJM SCALE). Tirzepatide 15mg weekly produces -20.9% over 72 weeks, an absolute gain of >12 percentage points. The posology advantage (1 weekly injection vs 1 daily) and 2.5x superior efficacy make liraglutide obsolete as first-line weight loss agent.

Versus dulaglutide (Trulicity): dulaglutide is a weekly GLP-1 agonist with modest weight loss (-3 to -4 kg at 1.5mg). Tirzepatide is 4-5x superior on weight outcomes. Direct comparison awaits SURPASS-CVOT (2025-2026 results) for cardiovascular events.

Versus basal insulin: SURPASS-3 and SURPASS-5 show that adding tirzepatide to antidiabetic therapy outperforms titrating basal insulin, without weight gain or hypoglycemia. Insulin remains essential in type 1 diabetes and acute type 2 decompensation, but as a type 2 intensification agent, tirzepatide is superior.

Versus bariatric surgery (sleeve, bypass): surgery remains the absolute efficacy reference (-25 to -30% at 1 year for Roux-en-Y bypass), but tirzepatide 15mg approaches it (-20.9% at 72 weeks) without invasive intervention, without post-operative nutritional deficiencies, and with a reversible profile. SURMOUNT-4 data remind us however that discontinuation triggers rapid weight regain, unlike post-surgery states.

Versus bupropion-naltrexone (Contrave/Mysimba), orlistat (Xenical), phentermine-topiramate (Qsymia): these agents produce 3-10% weight loss and are eclipsed by tirzepatide (2-7x more effective by comparison). Their residual advantages: oral form, much lower cost, no injection requirement.

Research positioning: tirzepatide is today's peptide of choice for exploratory protocols combining maximal metabolic efficacy and documented tolerance profile. Its data maturity surpasses retatrutide's and rivals semaglutide's, while offering a higher intensity of effect than the mono-agonist.

Full guide: Tirzepatide — mechanism, studies, dose comparison

Tirzepatide 10mg Weight Loss

Metabolism

01
Mechanism of action

02Clinical studies

03
Research protocols

Asepsis

Solvent

Introduction

Solubilization

04Storage & handling

Similar peptides

Metabolism

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents